Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 256 participants.
Also called NCT05226897
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 256 participants
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
- Registry
-
NCT05226897
-
- Other papers using this trial's data
- A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05226897. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-12 (actual); primary completion 2022-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- YYC405-T
- Intervention (Drug)
- Metformin≥1000mg
- Intervention (Drug)
- Dapagliflozin 10mg
- Intervention (Drug)
- YYC405-T placebo
- Lead sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05226897- Content hash
7413ea6cb85300e5af9f2b609ac3b054676973cbc112265a99a5ed516ff224fc